Snapshot

The surgical robotics market generated roughly $9.2 B in revenue in 2025, with Intuitive Surgical (ISRG) commanding approximately 83.5% market share. The global installed base of da Vinci systems reached 11,395 units by March 2026, with over 3.15 million da Vinci procedures performed in FY2025 — up 18% year-over-year. Robotic penetration of eligible surgical procedures globally remains in the low-to-mid teens (roughly 15%), and in many specialties — general surgery, gynecology, thoracic — it is far lower. Orthopedic surgical robotics is a parallel market: Stryker's Mako has passed 3,000 installations and 1.5 million cumulative procedures, mostly knee and hip replacement. Spine robotics is smaller: Globus Medical's ExcelsiusGPS has passed 120,000 cumulative procedures. Medtronic's Hugo system received FDA clearance in December 2025 for urology and completed its first U.S. commercial case in February 2026, making it the first credible challenger to da Vinci in soft-tissue robotics in the U.S.

Hospitals buy surgical robot systems for $0.5M–$2.5M each, then pay $600–$1,500 per procedure in disposable instruments plus $50K–$250K/year in service contracts. ISRG collected $10.06B in FY2025 — 60% from per-procedure instruments/accessories. With roughly 15% of eligible procedures done robotically worldwide, the installed base has room to grow several-fold before saturation at current procedure volumes.

The product & how money is made

A surgical robot system is a capital device — typically a surgeon console, a patient-side cart with articulated instrument arms, and a vision tower — that a hospital buys or leases. The surgeon sits at the console and controls miniaturized instruments inside the patient via a 3D camera feed. The robot translates hand movements into precise micro-movements, filters out tremor, and allows access to tight anatomical spaces that open surgery and standard laparoscopy cannot easily reach.

Three distinct product categories:

• Soft-tissue surgical robots (ISRG da Vinci, Medtronic Hugo): prostatectomy, hysterectomy, colorectal, thoracic, hernia, and general surgery. Highest-revenue segment.
• Orthopedic surgical robots (Stryker Mako): total knee, partial knee, total hip, shoulder, and spine. The robot pre-plans bone cuts from a CT scan and constrains the saw to the planned path.
• Spine navigation robots (Globus Medical ExcelsiusGPS): pedicle screw and interbody cage placement with sub-millimeter accuracy via real-time imaging and robotic arm guidance.

Revenue splits into three streams, demonstrated by ISRG's FY2025 breakdown:

ISRG Q1-2026 earnings release (stocktitan.net); FY2025 preliminary results (sahmcapital.com); pricing data from R2 Surgical and grabarobot.com (2025/2026 editions).

The razor-and-blade model means every system placed generates recurring revenue for the life of the robot (typically 7–10 years). Instruments/accessories + services together (75% of ISRG revenue) grow in lockstep with procedure volume, not new system sales. Stryker's Mako and Globus's ExcelsiusGPS follow the same logic: the robot places implants and instruments that Stryker/Globus manufacture, so each procedure drives implant and disposable revenue.

Demand

Contracted / visible demand

Surgical robot demand is not "contracted" in the way a data-center lease is. Hospitals buy or lease systems and then perform procedures. The contracted-demand equivalent is the installed base of systems that must be fed with consumables and service contracts. contracted

• ISRG installed base: 11,395 da Vinci + 1,041 Ion = 12,436 systems as of March 31, 2026. Each active da Vinci drives roughly 277 procedures/year (3.15M procedures / 11,395 systems FY2025), generating approximately $170K–$415K/year in instrument revenue per system. est.
• ISRG system placements: 1,721 da Vinci + 195 Ion in FY2025, accelerating to 431 da Vinci + 52 Ion in Q1-2026 alone. The da Vinci 5 (latest generation) comprised 232 of Q1-2026 placements.
• Stryker Mako: 3,000+ systems globally, 1.5M+ cumulative procedures. Record placements in Q4 2025 (exact figure not disclosed).
• Globus Medical ExcelsiusGPS: 120,000+ cumulative procedures; Q4 2025 was a record quarter for GPS placements in both dollars and units (exact count not disclosed). Enabling Technologies revenue was $55.6M in Q4 2025.
• Medtronic Hugo: early-stage U.S. launch. Installed at Cleveland Clinic, Duke, and Wake Forest as of Q1 2026. Available in 35+ countries outside the U.S. with "tens of thousands" of cumulative international procedures.

Forecast demand

• Low penetration = long runway. 72.6% of U.S. hospitals had at least one surgical robot by 2023 (AHA), but procedure penetration is the real metric. Robotic prostatectomy is 87% penetrated in the U.S.; hysterectomy ~61%; general surgery, colorectal, thoracic, and hernia are far earlier — and outside the U.S. penetration lags by 5–10 years. est.
• ISRG guidance: 13.5%–15.5% da Vinci procedure growth in 2026.
• Orthopedic robotics penetration: Stryker says roughly two-thirds of U.S. knees and one-third of U.S. hips are now performed robotically on Mako. Shoulder and spine applications launched in late 2024 / H2 2025, opening new procedure categories.
• Market-level forecast: global surgical robotics market projected from $9.2B (2025) to $38.4B (2034) at a 17.2% CAGR. The instruments & accessories sub-segment (68% of the market) is the fastest-growing piece. est.
• International expansion is the largest growth vector. ISRG's OUS da Vinci procedures grew 23% in FY2025 vs. 18% overall. Much of Asia, Latin America, the Middle East, and Eastern Europe have minimal robotic surgery infrastructure today.

ISRG Q1-2026 earnings release; ISRG FY2025 preliminary results; Stryker Q4-2025 earnings (dafinchi.ai); Globus Medical Q4-2025 earnings (MarketBeat); Medtronic FDA press release Dec 2025; GM Insights surgical robots market report 2025; AHA hospital survey (2023).

Supply

Manufacturing capacity

• ISRG manufactures da Vinci and Ion systems in Sunnyvale, CA and Mexicali, Mexico. FY2025 output: 1,916 total systems (1,721 da Vinci + 195 Ion). Q1-2026 run-rate: ~1,932/year (483 x 4). The da Vinci 5 was described as "limited supply through 2025" as manufacturing scaled; by Q1-2026, 232 of 431 da Vinci placements were dV5 (54%), suggesting supply constraints are easing.
• Stryker manufactures Mako at U.S. facilities and has expanded production for the Mako 4 (fourth-generation) platform. Mako-specific manufacturing capacity not disclosed; the 3,000+ installed base was built over ~7 years since acquisition of Mako Surgical in 2013.
• Globus Medical manufactures ExcelsiusGPS at its Audubon, PA headquarters. Smaller production volumes; Q4 2025 was the first quarter with record unit sales.
• Medtronic manufactures Hugo at facilities supporting its global Surgical Innovations segment. International installations span 35+ countries. U.S. manufacturing capacity is scaling from near-zero commercial base.

Bottlenecks

• Surgeon training is the binding constraint, not hardware manufacturing. A surgeon requires 20–50 proctored cases to become proficient. Hospital credentialing committees must approve each surgeon individually, limiting how fast procedure volumes grow even after a system is installed.
• Hospital capital budgets: at $0.5M–$2.5M per system, robots compete with other capital priorities. The shift toward operating leases and usage-based pricing (ISRG placed 118 systems on usage-based leases in Q1-2026) lowers the upfront barrier.
• OR space: each robot requires a dedicated operating room setup. Older hospital layouts may need renovation to accommodate the patient-side cart and console.
• FDA regulatory clearance gates new entrants. Hugo's U.S. clearance covers only urology so far; gynecology and general surgery clearances are pending. J&J's Ottava system is pre-clearance. Each new indication requires a separate clinical study.
• Tariffs: ISRG flagged a 1.0% of revenue tariff impact in 2026 guidance for internationally sourced manufacturing components.

ISRG Q1-2026 earnings release; Stryker AAOS 2025 presentation; Globus Medical Q4-2025 earnings; Medtronic Hugo FDA press release; R2 Surgical (2025).

The gap

Roughly 85% of eligible soft-tissue procedures worldwide are still done without a robot. In orthopedics, U.S. knee penetration is high (~67% on Mako) but hip, shoulder, and spine are early, and international orthopedic robotics is nascent. The da Vinci 5 commands a ~30% premium over the Xi it replaces, and instrument pricing has been stable for years. Hugo targets price-sensitive buyers — per-procedure cost roughly 15–20% below da Vinci, service contracts described as 40–50% lower. est. Whether Hugo takes share or expands the market (by making robotics affordable for hospitals that could not justify da Vinci) is the central competitive question.

ISRG filings; grabarobot.com pricing data (2026); GM Insights market report; Stryker Q4-2025 commentary.

The players

*MDT's P/E reflects the whole company ($33.5B revenue across cardiovascular, neuroscience, diabetes, and surgical). Hugo is a tiny fraction of that; the multiple does not price robotics specifically.

Revenue exposure to surgical robotics differs dramatically. ISRG is 100% surgical robotics. SYK's Mako sits inside the $9.47B Orthopaedics segment (38% of total revenue); Mako-specific revenue is not broken out but drives implant pull-through across the segment. GMED's Enabling Technologies (including ExcelsiusGPS) was $55.6M in Q4 2025 — roughly 7% of quarterly revenue — but the robot drives spine implant sales across the larger musculoskeletal business ($741M in Q4). MDT's Hugo is pre-revenue-scale in the U.S.

Competitive positioning:

• ISRG: 12,400+ systems, 3.15M annual procedures, surgeon training locked in, 75% recurring revenue. The da Vinci 5 adds force feedback and a larger instrument library.
• SYK: dominant in orthopedic robotics. Mako drives implant pull-through — when a hospital buys Mako, it buys Stryker implants. Expanding from knee/hip into shoulder and spine on the same platform.
• MDT: $33.5B parent company with existing hospital relationships. Modular arm design (arms repositioned between ORs). U.S. clearance currently urology-only; broader clearances pending.
• GMED: spine-focused after the 2023 NuVasive merger ($2.94B combined revenue). ExcelsiusGPS is the leading spine robot by installed procedures. Nevro acquisition (2025, $99.7M Q4 revenue) adds neuromodulation.

Market caps and P/E from stockanalysis.com and companiesmarketcap.com (Jun 2, 2026). Revenue from company earnings releases.

The price of exposure

ISRG (pure-play): $142.5B market cap on $10.06B FY2025 revenue growing ~20%/year. That is roughly $11,500 per installed da Vinci/Ion system (market cap / 12,436 systems). FY2025 net income approximately $2.8B on $10.06B revenue (28% net margin); free cash flow approximately $2.5B. est.

SYK (robotics embedded in ortho): $112.4B buys the entire company, not just Mako. Mako-specific revenue is not disclosed; the Orthopaedics segment is $9.47B. At $112.4B the whole company trades at ~4.5x total revenue on ~11% growth.

GMED (smallest, cheapest multiple): $10.6B at 18.2x trailing P/E. FY2025 revenue $2.94B (including $293.6M from Nevro). FY2026 guidance: $3.18–$3.22B (8–10% growth) with EPS of $4.40–$4.50 (11–13% growth). At 16.3x forward P/E, the market prices GMED more like traditional medtech than a robotics growth story.

MDT (Hugo is optionality): $94.7B on $33.5B revenue. Hugo is currently immaterial to financials — the Medical Surgical segment ($8.41B FY2025) grew only 0.8% organically. If Hugo takes 10–20% of the soft-tissue robotics market over 5–10 years, that could be $1–2B of incremental annual revenue against Medtronic's base. est. The stock trades at ~21x earnings, a discount to the medtech peer group.

Prices from stockanalysis.com and companiesmarketcap.com (Jun 2, 2026). Revenue and earnings from filings cited above.

What to deep-dive next

• ISRG 10-K (FY2025): installed base by geography, procedure mix by specialty, da Vinci 5 vs. Xi placement split, operating lease vs. purchase mix, and whether utilization per system (procedures/system/year) is flat or rising.
• Hugo FDA clearance timeline: Medtronic's pending gynecology and general surgery submissions. Broader U.S. clearance determines whether Hugo is a urology niche or a real da Vinci competitor.
• J&J Ottava: late-stage development, pre-FDA submission. Entry creates a three-way dynamic in soft-tissue (ISRG, MDT, JNJ) that could pressure pricing.
• Stryker Mako spine and shoulder ramp: launched late 2024/H2 2025 in limited release. Full U.S. launch of Mako Spine expected H2 2025 — verify adoption data in SYK's FY2025 10-K.
• GMED ExcelsiusGPS unit economics: Globus is shifting toward more operating leases in 2026 (management commentary), changing revenue recognition timing.
• AI integration: ISRG is building tissue characterization and intraoperative imaging AI into the da Vinci 5. Medtronic has Touch Surgery analytics. Track FDA clearances for AI-assisted surgical features.

Sources & confidence

• ISRG Q1-2026 earnings release (stocktitan.net, Apr 2026) — installed base 11,395 da Vinci / 1,041 Ion, Q1 revenue $2.77B, FY2026 guidance.
• ISRG FY2025 preliminary results (sahmcapital.com, Jan 2026) — $10.06B revenue, 1,721 da Vinci / 195 Ion placed, 3.15M procedures.
• Stryker Q4-2025 earnings (dafinchi.ai, Jan 2026) — 3,000+ Mako installed, 1.5M+ cumulative procedures, Mako 4 launch.
• Stryker AAOS 2025 presentation (stryker.com, Feb 2025) — Mako 4 details, spine/shoulder expansion timelines.
• Globus Medical Q3-2025 earnings release (stocktitan.net) — $769M Q3 revenue, enabling tech $28M (Q3), FY2025 guidance.
• Globus Medical Q4-2025 earnings (marketbeat.com, Feb 2026) — $826.4M Q4 revenue, enabling tech $55.6M (record), 120K+ cumulative GPS procedures, FY2026 guidance $3.18–3.22B.
• Medtronic FY2025 earnings release (news.medtronic.com, May 2025) — $33.54B revenue, segment breakdown.
• Medtronic Hugo FDA clearance (news.medtronic.com, Dec 3, 2025) — cleared for urologic procedures, Expand URO study.
• Medtronic Hugo first U.S. case (acaderesearch.com, Feb 2026) — Cleveland Clinic, Dr. Jihad Kaouk, prostatectomy.
• Surgical robot pricing (grabarobot.com, 2026 edition; r2surgical.com, 2025 edition) — system and per-procedure cost comparisons.
• GM Insights surgical robots market report (gminsights.com, 2025) — $9.2B market (2025), 17.2% CAGR, 83.5% ISRG share, 72.6% U.S. hospital penetration.
• Market.us robotic surgery statistics (media.market.us, 2026) — penetration rates by specialty, historical procedure volumes.
• Market cap and valuation data (stockanalysis.com, companiesmarketcap.com, Jun 2, 2026) — ISRG $142.5B, SYK $112.4B, MDT $94.7B, GMED $10.6B.

Confidence: Company-reported installed base, revenue, and procedure counts are from primary earnings releases (high confidence). Pricing data is from third-party aggregators (R2 Surgical, GrabARobot) and represents list/negotiated ranges, not verified transaction prices. Market size and CAGR figures ($9.2B, 17.2%) are from GM Insights — different research firms produce different numbers. Penetration rates by specialty are from published studies and AHA survey data but may lag 1–2 years.